When we compared patients with certain aPL for differences in their NPSLE manifestations we found that patients with anti-β2GPI IgM have an almost six times higher likelihood of having nonspecific, intractable headaches (Table 4) or ischemic stroke (Table 5) than patients negative for these antibodies. The gene discussed is CD40LG; the disease is ischemic stroke.